ConductScience.org, home

Trial · NCT04449029

Results by group362

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number of Participants Achieving Sustained Virologic Response (SVR)GSK3228836 for 24 Weeks (WK) (on NA Therapy)6Participants
Number of Participants Achieving Sustained Virologic Response (SVR)GSK3228836 for 12+12 WK (on NA Therapy)6Participants
Number of Participants Achieving Sustained Virologic Response (SVR)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)2Participants
Number of Participants Achieving Sustained Virologic Response (SVR)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)0Participants
Number of Participants Achieving Sustained Virologic Response (SVR)GSK3228836 for 24 WK (Not on NA Therapy)7Participants
Number of Participants Achieving Sustained Virologic Response (SVR)GSK3228836 for 12+12 WK (Not on NA Therapy)4Participants
Number of Participants Achieving Sustained Virologic Response (SVR)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)1Participants
Number of Participants Achieving Sustained Virologic Response (SVR)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)0Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQGSK3228836 for 24 Weeks (WK) (on NA Therapy)16Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQGSK3228836 for 12+12 WK (on NA Therapy)9Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQGSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)8Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQPlacebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)4Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQGSK3228836 for 24 WK (Not on NA Therapy)17Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQGSK3228836 for 12+12 WK (Not on NA Therapy)10Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQGSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)6Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQPlacebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)1Participants
Number of Participants With Categorical Changes From Baseline in HBsAg ValuesGSK3228836 for 24 Weeks (WK) (on NA Therapy)HBsAg< LLOQ, at baseline0Participants
Number of Participants With Categorical Changes From Baseline in HBsAg ValuesGSK3228836 for 12+12 WK (on NA Therapy)HBsAg< LLOQ, at baseline0Participants
Number of Participants With Categorical Changes From Baseline in HBsAg ValuesGSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)HBsAg< LLOQ, at baseline0Participants
Number of Participants With Categorical Changes From Baseline in HBsAg ValuesPlacebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)HBsAg< LLOQ, at baseline0Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04449029/results